UBS Global Biopharma Conference 2026
Logotype for Praxis Precision Medicines Inc

Praxis Precision Medicines (PRAX) UBS Global Biopharma Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Praxis Precision Medicines Inc

UBS Global Biopharma Conference 2026 summary

16 Nov, 2026

Ulixacaltamide regulatory outlook

  • Jan. 29 PDUFA is the key near-term decision; management said confidence in approval was high after a late-cycle meeting it characterized as label-focused.

  • Remaining regulatory work includes agreeing on potential PMCs/PMRs and finalizing the label; manufacturing activities continued, with significant inventory and dual capacity for most of the process.

  • Broad adult essential tremor studies showed every subgroup nominally superior to placebo; management expects no meaningful label limits from study inclusion criteria or drug interactions.

  • Management expects scheduling may occur, but said Schedule IV, Schedule V or no scheduling would not change its launch approach; neurologists are the target prescribers.

Commercial strategy and long-term use

  • Initial treatment can cause dizziness and brain fog for some patients; management said these effects ease with continued use at 20 mg, making controlled patient experience central to launch execution.

  • Launch plans include significant resources and coverage across the prescribing base, aiming to build demand while managing patient experience; management estimated the opportunity at $36B.

  • Praxis Horizon is operational for end-to-end prescription workflows, linking EMR prescribing, prior-authorization data and prescription routing through a dedicated pharmacy channel.

  • Long-term follow-up showed continued improvement; the goal is ~200 patients with two years of follow-up, with additional data expected as follow-up completes.

  • Essential tremor treatment is chronic, and management said it intends to keep patients on therapy as long as possible because the condition progressively reduces function and has no cure.

Pipeline and upcoming milestones

  • The portfolio includes 21 programs and two NDAs; three ulixacaltamide extension studies in restless legs syndrome, Parkinson’s tremor and autism spectrum disorder were set to start soon.

  • Management expects data from several programs next year; two next-generation ulixacaltamide programs are in IND-enabling work, while an active-delivery patch is targeted to enter the clinic next year.

  • Relutrigine’s PDUFA for SCN2A/SCN8A developmental encephalopathies is expected in a little over a month; management said FDA discussions were less advanced than for ulixacaltamide.

  • Management cited 300,000 U.S. patients in the relevant population and a $5B-$8B peak total market opportunity for relutrigine.

  • EMERALD data in broader developmental and epileptic encephalopathies were targeted for year-end, subject to investigator closeout; the study has ~200 patients across many sites and countries.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Praxis Precision Medicines